Similarly, analysis of tumors from ipilimumab-refractory patients showed that mutations in the IFN-γ pathway genes IFNGR1/2, JAK1/2 and IRF1 inhibit the response of tumor cells to IFN-γ signaling (39). This evidence concerns the gene IFNG and neoplasm.